Agreed....
P value low
n very low (15 !!)
means drug effect size is up...
Wait till our P3 comes in when n is greater than 15 !?! What is that going to do to P on the assumption that drug effect size stays constant? (As it has done in all the other clinical trials and studies).
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-6
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $75.30M | |||
| Open | High | Low | Value | Volume |
| 21.0¢ | 22.0¢ | 20.5¢ | $179.1K | 836.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 202114 | 21.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 21.5¢ | 3079 | 2 |
View Market Depth
| Last trade - 15.02pm 11/10/2024 (20 minute delay) ? |
| PAR (ASX) Chart |